Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats
- PMID: 7643100
- DOI: 10.1046/j.1471-4159.1995.65031213.x
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats
Abstract
The effect of selective inhibition of monoamine oxidase (MAO) subtypes A and B on striatal metabolism of DOPA to dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and 4-hydroxy-3-methoxyphenylacetic acid (homovanillic acid; HVA) was studied in halothane-anesthetized rats 3 weeks after unilateral 6-hydroxydopamine lesion of the substantia nigra. Implantation of bilateral microdialysis probes allowed simultaneous quantitation of metabolite production on lesioned and control sides. The DOPA was administered as a 15-min bolus of 1 mM solution in the striatal microdialysate. Rats were pretreated with the selective MAO-A inhibitor clorgyline, or the selective MAO-B inhibitors deprenyl or TVP-101 [2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride]. Intrastriatal infusion of DOPA caused an increased efflux of DA, DOPAC, and HVA, which was greater on the intact side. Clorgyline, but not deprenyl or TVP-101, increased post-DOPA DA efflux on both intact and lesioned sides. Clorgyline also caused a marked suppression of post-DOPA DOPAC and HVA effluxes, whereas only mild effects were produced by the MAO-B inhibitors. There was no evidence for a differential effect of MAO-B inhibition on efflux of DA or metabolites in the lesioned as compared with the control striatum. The results indicate a major role for MAO-A in DA metabolism both intra- and extraneuronally in the rat striatum.
Similar articles
-
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.J Neurochem. 1996 Oct;67(4):1532-9. doi: 10.1046/j.1471-4159.1996.67041532.x. J Neurochem. 1996. PMID: 8858937
-
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.J Neural Transm Park Dis Dement Sect. 1995;10(2-3):79-89. doi: 10.1007/BF02251224. J Neural Transm Park Dis Dement Sect. 1995. PMID: 9620056
-
Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.Brain Res. 1996 Oct 28;738(1):53-9. doi: 10.1016/0006-8993(96)00761-5. Brain Res. 1996. PMID: 8949927
-
Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties).Pharmacol Toxicol. 2001 Nov;89(5):217-24. doi: 10.1034/j.1600-0773.2001.d01-151.x. Pharmacol Toxicol. 2001. PMID: 11881974 Review.
-
[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].Vopr Med Khim. 1997 Nov-Dec;43(6):482-93. Vopr Med Khim. 1997. PMID: 9503565 Review. Russian.
Cited by
-
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.Rambam Maimonides Med J. 2010 Jul 2;1(1):e0003. doi: 10.5041/RMMJ.10003. Print 2010 Jul. Rambam Maimonides Med J. 2010. PMID: 23908775 Free PMC article.
-
Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.Neurotox Res. 2017 Apr;31(3):334-347. doi: 10.1007/s12640-016-9686-5. Epub 2016 Dec 15. Neurotox Res. 2017. PMID: 27981510
-
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.J Neural Transm (Vienna). 2015 Feb;122(2):259-72. doi: 10.1007/s00702-014-1247-6. Epub 2014 Jun 7. J Neural Transm (Vienna). 2015. PMID: 24906468
-
Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.Br J Pharmacol. 2013 Nov;170(5):999-1013. doi: 10.1111/bph.12349. Br J Pharmacol. 2013. PMID: 23992249 Free PMC article.
-
Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice.Neurochem Res. 2004 Apr;29(4):741-6. doi: 10.1023/b:nere.0000018845.82808.45. Neurochem Res. 2004. PMID: 15098936
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical